Characterization of a genotype previously designated as CYP2A6 D-type:: CYP2A6*4B, another entire gene deletion allele of the CYP2A6 gene in Japanese

被引:18
作者
Ariyoshi, N
Sekine, H
Saito, K
Kamataki, T
机构
[1] Hokkaido Univ, Lab Drug Metab, Div Pharmacobiodynam, Grad Sch Pharmaceut Sci, Sapporo, Hokkaido, Japan
[2] Sapporo Med Univ Hosp, Dept Pharm, Sapporo, Hokkaido, Japan
来源
PHARMACOGENETICS | 2002年 / 12卷 / 06期
关键词
cytochrome P450; genetic polymorphism; genotyping; family study;
D O I
10.1097/00008571-200208000-00012
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
CYP2A6 is known as an enzyme responsible for the metabolism of several clincally used drugs such as tegafur. Previously, we found two novel genotypes of the CYP2A6 gene, D-type and E-type, and the E-type was clarified to be homozygous for the CYP2A6* 4A allele. On the other hand, since the D-type was reported to lack regions from at least intron 5 to a part of exon 9 of the CYP2A6 gene, it caused a misunderstanding that the D-type would be a partial CYP2A6 gene-deleted allele. In this paper, we demonstrate that the D-type is a genotype heterozygous for the CYP2A6*4A and another novel entire CYP2A6 gene-deleted allele, CYP2A6*4B, by analyzing a Japanese family including parents genotyped as the CYP2A6*4A/4A and CYP2A6* 1A/*4B, respectively.
引用
收藏
页码:501 / 504
页数:4
相关论文
共 10 条
[1]   Structural characterization of a new variant of the CYP2A6 gene (CYP2A6*1B) apparently diagnosed as heterozygotes of CYP2A6*1A and CYP2A6*4C [J].
Ariyoshi, N ;
Takahashi, Y ;
Miyamoto, M ;
Umetsu, Y ;
Daigo, S ;
Tateishi, T ;
Kobayashi, S ;
Mizorogi, Y ;
Loriot, MA ;
Stücker, I ;
Beaune, P ;
Kinoshita, M ;
Kamataki, T .
PHARMACOGENETICS, 2000, 10 (08) :687-693
[2]  
Ikeda K, 2000, CLIN CANCER RES, V6, P4409
[3]   CYP2A6 gene deletion reduces susceptibility to lung cancer [J].
Miyamoto, M ;
Umetsu, Y ;
Dosaka-Akita, H ;
Sawamura, Y ;
Yokota, J ;
Kunitoh, H ;
Nemoto, N ;
Sato, K ;
Ariyoshi, N ;
Kamataki, T .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 261 (03) :658-660
[4]   Homologous unequal cross-over within the human CYP2A gene cluster as a mechanism for the deletion of the entire CYP2A6 gene associated with the poor metabolizer phenotype [J].
Nunoya, K ;
Yokoi, T ;
Takahashi, Y ;
Kimura, K ;
Kinoshita, M ;
Kamataki, T .
JOURNAL OF BIOCHEMISTRY, 1999, 126 (02) :402-407
[5]   A new deleted allele in the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride (SM-12502) [J].
Nunoya, K ;
Yokoi, T ;
Kimura, K ;
Inoue, K ;
Kodama, T ;
Funayama, M ;
Nagashima, K ;
Funae, Y ;
Green, C ;
Kinoshita, M ;
Kamataki, T .
PHARMACOGENETICS, 1998, 8 (03) :239-249
[6]  
Nunoya KI, 1996, J PHARMACOL EXP THER, V277, P768
[7]   Identification and characterisation of novel polymorphisms in the CYP2A locus:: implications for nicotine metabolism [J].
Oscarson, M ;
McLellan, RA ;
Gullstén, H ;
Agúndez, JAG ;
Benítez, J ;
Rautio, A ;
Raunio, H ;
Pelkonen, O ;
Ingelman-Sundberg, M .
FEBS LETTERS, 1999, 460 (02) :321-327
[8]   CYP2A6: a human coumarin 7-hydroxylase [J].
Pelkonen, O ;
Rautio, A ;
Raunio, H ;
Pasanen, M .
TOXICOLOGY, 2000, 144 (1-3) :139-147
[9]  
WALTER BA, 1994, P 6 N AM ISSX M RAYL, P187
[10]   Genetic polymorphism of drug metabolizing enzymes:: New mutations in CYP2D6 and CYP2A6 genes in Japanese [J].
Yokoi, T ;
Kamataki, T .
PHARMACEUTICAL RESEARCH, 1998, 15 (04) :517-524